Placebo-Controlled phase III Study of lenograstim (Glycosylated recombinant human granulocyte colony-Stimulating factor) in Aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration-Reference-Cited by-同舟云学术

Placebo-Controlled phase III Study of lenograstim (Glycosylated recombinant human granulocyte colony-Stimulating factor) in Aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration

Published:1997-01 Issue:3-4 Volume:25 Page:289-300
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Gisselbrecht Christian,Haioun Corinne,Lepage Eric,Bastion Yves,Tilly Hervé,Bosly André,Dupriez Brigitte,Marit Gerald,Herbrecht Raoul,Deconinck Eric,Marolleau Jean Pierre,Yver Antoine,Dabouz-Harrouche Farida,Coiffier Bertrand,Reyes Felix

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428199709114168

Reference29 articles.

1. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.

2. Identification of Major Prognostic Subgroups of Patients with Large-Cell Lymphoma Treated with m-BACOD or M-BACOD

3. Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma;The Oncologist;2022-03-15

2. Prevention of neutropenia as an important factor in successful chemotherapy for head and neck cancer;Head and Neck Tumors (HNT);2021-11-12

3. Comparison of Primary and Secondary Prophylaxis Using PEGylated Recombinant Human Granulocyte–Stimulating Factor as a Cost-Effective Measure in Malignant Neoplasms: A Multicenter Retrospective Study;Frontiers in Pharmacology;2021-10-29

4. Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis;Scientific Reports;2019-10-25

5. Risk of pulmonary toxicity of bleomycin and filgrastim;Journal of Oncology Pharmacy Practice;2018-10-14